<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Teclistamab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Teclistamab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Teclistamab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="140066" href="/d/html/140066.html" rel="external">see "Teclistamab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F57428725"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cytokine release syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving teclistamab. Initiate treatment with teclistamab step-up dosing schedule to reduce risk of CRS. Withhold teclistamab until CRS resolves or permanently discontinue based on severity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurologic toxicity including immune effector cell-associated neurotoxicity syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS) and serious and life-threatening reactions, can occur with teclistamab. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold teclistamab until neurologic toxicity resolves or permanently discontinue based on severity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk Evaluation and Mitigation Strategy Program:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because of the risk of CRS and neurologic toxicity, including ICANS, teclistamab is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TECVAYLI and TALVEY REMS.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57448400"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tecvayli</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58872670"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Tecvayli</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57428757"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-BCMA;</li>
<li>
                        Antineoplastic Agent, Anti-CD3;</li>
<li>
                        Antineoplastic Agent, Bispecific T Cell Engager;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F57460457"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Due to the risk of cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), patients should be hospitalized for 48 hours after all doses within the teclistamab step-up dosing schedule (step-up doses 1 and 2, as well as the first treatment dose).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Premedication:</i> Premedicate 1 to 3 hours prior to teclistamab step-up dose 1, step-up dose 2, and the first treatment dose to reduce the risk and severity of CRS. Premedication may be necessary prior to subsequent doses in patients who repeat doses within the teclistamab step-up dosing schedule (following a dose delay), or who experienced CRS following the prior teclistamab dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Premedication should include a corticosteroid (IV or oral dexamethasone 16 mg), a histamine H<sub>1</sub> antagonist (IV or oral diphenhydramine 50 mg or equivalent), and antipyretics (oral or IV acetaminophen 650 to 1,000 mg or equivalent).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i> Administer prophylactic antimicrobials according to clinical practice guidelines. Consider antiviral prophylaxis prior to teclistamab initiation to prevent herpes zoster reaction, per clinical guidelines.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1c12cde-98c7-41e9-80b8-0893e9934cc7">Multiple myeloma, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed/refractory: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Day 1 (step-up dose 1): <b>SUBQ:</b> 0.06 mg/kg once.</p>
<p style="text-indent:-2em;margin-left:4em;">Day 4 (step-up dose 2): <b>SUBQ:</b> 0.3 mg/kg once. <b>Note: </b>Step-up dose 2 may be administered 2 to 4 days after step-up dose 1 and, if necessary, up to 7 days after step-up dose 1 to allow for resolution of adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">Day 7 (first treatment dose):<b> SUBQ:</b> 1.5 mg/kg once. <b>Note: </b>The first treatment dose may be administered 2 to 4 days after step-up dose 2 and, if necessary, up to 7 days after step-up dose 2 to allow for resolution of adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">Weekly dosing schedule: <b>SUBQ:</b> 1.5 mg/kg once weekly, starting 1 week after the first treatment dose and weekly thereafter until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35661166']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35661166'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Recommendations for Restarting Teclistamab<sup>a</sup> After Dose Delay</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Last teclistamab dose administered</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Duration of delay from the last teclistamab dose administered</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Action</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Patients should be hospitalized for 48 hours after all doses within the teclistamab step-up dosing schedule.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Administer premedication prior to teclistamab administration and monitor accordingly.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Consider risk/benefit of restarting teclistamab if a dose delay of &gt;28 days occurs due to an adverse reaction.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Step-up dose 1</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;7 days</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Restart teclistamab<sup>b</sup> step-up dosing schedule at 0.06 mg/kg (step-up dose 1).</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Step-up dose 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8 to 28 days</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Repeat teclistamab<sup>b</sup> step-up dose 2 (0.3 mg/kg) and resume the step-up dosing schedule.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;28 days<sup>c</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Restart teclistamab<sup>b</sup> step-up dosing schedule at 0.06 mg/kg (step-up dose 1).</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Any treatment dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8 to 28 days</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Continue teclistamab weekly dosing schedule at 1.5 mg/kg once weekly.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;28 days<sup>c</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Restart teclistamab<sup>b</sup> step-up dosing schedule at 0.06 mg/kg (step-up dose 1).</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F57460459"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Kidney function estimated using the modification of diet in renal disease (MDRD) equation.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 30 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant difference in teclistamab pharmacokinetics were observed based on eGFR 30 to 89 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (effects on teclistamab pharmacokinetics are unknown).</p></div>
<div class="block doha drugH1Div" id="F57460460"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin ≤ ULN with AST &gt; ULN or total bilirubin &gt;1 to 1.5 times ULN with any AST): There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant difference in teclistamab pharmacokinetics was observed based on mild hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe impairment (total bilirubin &gt;1.5 times ULN with any AST): There are no dosage adjustments provided in the manufacturer's labeling (effects on teclistamab pharmacokinetics are unknown).</p></div>
<div class="block doo drugH1Div" id="F57460461"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society </i>
<i>of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> The dosing in the FDA-approved prescribing information should be followed in all patients, regardless of obesity status. If a patient with a BMI ≥30 kg/m<sup>2 </sup>experiences high-grade toxicity from systemic anticancer therapy, the same dosage modification recommendations should be followed for all patients, regardless of obesity status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F57460465"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab dose reductions are not recommended for adverse reactions; however, dose delays may be necessary to manage toxicities. Refer to "Dosing: Adult" for recommendations on restarting teclistamab (step-up doses) after dose delays.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytokine release syndrome:</b> If cytokine release syndrome (CRS) is suspected, interrupt teclistamab until resolved; manage according to the table below and per clinical practice guidelines. Supportive therapy for CRS may include intensive care for severe or life-threatening CRS. Consider laboratory testing to monitor for disseminated intravascular coagulation, hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function. Evaluate and treat other causes of fever, hypoxia, and hypotension.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Teclistamab-Related CRS Management</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>CRS grade</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Symptoms</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Actions</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Fever may be masked by antipyretics or anticytokine therapy.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>b</sup> Tocilizumab may be considered in the management of persistent grade 2, severe (grade 3), or life-threatening (grade 4) CRS associated with bi-specific T-cell engager (BiTE) therapy (EMN [Ludwig 2023]; Lee 2014; Maude 2014); tocilizumab or corticosteroids were used (in the teclistamab clinical trial) to manage CRS in some patients (Martin 2023; Moreau 2022).</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>c</sup> CPAP = continuous positive airway pressure; BiPAP = bilevel positive airway pressure.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 1</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a </sup>attributed to CRS.</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until CRS resolves. Administer premedication prior to the next teclistamab dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a</sup> attributed to CRS, with hypotension responsive to fluids and not requiring vasopressors and/or oxygen requirement of low-flow nasal cannula (≤6 L/minute) or blow-by.</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until CRS resolves. Administer premedication prior to the next teclistamab dose. Patients should be hospitalized for 48 hours following the next teclistamab dose.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a</sup> attributed to CRS, with hypotension requiring one vasopressor with or without vasopressin and/or oxygen requirement of high-flow nasal cannula (&gt;6 L/minute), face mask, nonrebreather mask, or Venturi mask.</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First occurrence of grade 3 CRS with duration &lt;48 hours:</p>
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until CRS resolves. Provide supportive therapy<sup>b</sup> as clinically necessary (may include intensive care). Administer premedication prior to the next teclistamab dose. Patients should be hospitalized for 48 hours following the next teclistamab dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Recurrent grade 3 CRS or grade 3 CRS with duration ≥48 hours:</p>
<p style="text-indent:0em;text-align:left;">Permanently discontinue teclistamab and provide supportive care<sup>b</sup> as clinically necessary (may include intensive care).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a</sup> attributed to CRS, with hypotension requiring multiple vasopressors (excluding vasopressin) and/or oxygen requirement of positive pressure (eg, CPAP, BiPAP, intubation, and mechanical ventilation).<sup>c</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue teclistamab and provide supportive care<sup>b</sup> as clinically necessary (may include intensive care).</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurologic toxicity: </b>Monitor for signs/symptoms of neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) and other neurotoxicities. Rule out other causes of neurologic signs/symptoms. Interrupt teclistamab at the first sign of neurologic toxicity, including ICANS, and consider neurology evaluation. Supportive therapy may include intensive care for severe or life-threatening neurologic toxicities. Manage according to the table below and per clinical practice guidelines.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Teclistamab-Related Neurologic Toxicity Management</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Actions</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for ICANS.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Management is determined by the most severe event (not attributable to any other cause).</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>If patient is arousable and able to perform immune effector cell-associated encephalopathy (ICE) assessment:</p>
<ul>
<li>
<p style="text-indent:0em;">Orientation (oriented to year, month, city, hospital = 4 points)</p></li>
<li>
<p style="text-indent:0em;">Naming (name 3 objects, eg, point to clock, pen, button = 3 points)</p></li>
<li>
<p style="text-indent:0em;">Following commands (eg, “show me 2 fingers” or “close your eyes and stick out your tongue” = 1 point)</p></li>
<li>
<p style="text-indent:0em;">Writing (ability to write a standard sentence = 1 point)</p></li>
<li>
<p style="text-indent:0em;">Attention (count backwards from 100 by 10 = 1 point)</p></li></ul>
<p style="text-indent:0em;text-align:left;">If unarousable and unable to perform ICE assessment (grade 4 ICANS = 0 points).</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Not attributable to any other cause.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Neurologic toxicity <b>(excluding ICANS)</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until neurologic toxicities/symptoms resolve or stabilize.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2 or grade 3 (first occurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until neurologic toxicities/symptoms improve to ≤ grade 1. Provide supportive therapy as clinically appropriate.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Recurrent grade 3 or grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue teclistamab. Provide supportive care as clinically appropriate (may include intensive care).</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Recommendations for management of teclistamab-related ICANS</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>ICANS grade<sup>a</sup></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Presenting symptoms<sup>b</sup></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Actions</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ICE score 7 to 9<sup>c</sup>, or depressed level of consciousness<sup>d </sup>(awakens spontaneously)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until ICANS resolves.</p>
<p style="text-indent:0em;text-align:left;">Monitor neurologic symptoms and consider consultation with neurologist/other specialists for further evaluation and management (eg, consideration for initiating seizure prophylaxis with nonsedating, antiseizure medication).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ICE score 3 to 6<sup>c</sup>, or depressed level of consciousness<sup>d</sup> (awakens to voice)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until ICANS resolves.</p>
<p style="text-indent:0em;text-align:left;">Administer dexamethasone 10 mg IV every 6 hours (or equivalent); continue dexamethasone until resolution to ≤ grade 1, then taper.</p>
<p style="text-indent:0em;text-align:left;">Monitor neurologic symptoms and consider consultation with neurologist/other specialists for further evaluation and management (eg, consideration for initiating seizure prophylaxis with nonsedating, antiseizure medication).</p>
<p style="text-indent:0em;text-align:left;">Patients should be hospitalized for 48 hours following the next teclistamab dose.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">ICE score 0 to 2<sup>c</sup>, <b>or </b></p>
<p style="text-indent:0em;text-align:left;">depressed level of consciousness<sup>d</sup> (awakens only to tactile stimulus), or seizures<sup>d</sup> (either any clinical seizure, focal or generalized, that resolves rapidly, <b>or</b> nonconvulsive seizures on EEG that resolve with intervention), <b>or</b></p>
<p style="text-indent:0em;text-align:left;">raised intracranial pressure (focal/local edema on neuroimaging<sup>d</sup>)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First occurrence of grade 3 ICANS:</p>
<p style="text-indent:0em;text-align:left;">Manage as per grade 2 ICANS. Provide supportive therapy as clinically appropriate (may include intensive care).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Recurrent grade 3 ICANS:</p>
<p style="text-indent:0em;text-align:left;">Permanently discontinue teclistamab.</p>
<p style="text-indent:0em;text-align:left;">Manage as per grade 2 ICANS. Provide supportive therapy as clinically appropriate.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ICE score 0<sup>c</sup>, <b>or</b></p>
<p style="text-indent:0em;text-align:left;">depressed level of consciousness<sup>d</sup> (either unarousable or requires vigorous/repetitive tactile stimuli to arouse, or stupor or coma), <b>or</b></p>
<p style="text-indent:0em;text-align:left;">seizures<sup>d</sup> (either life-threatening prolonged seizure &gt;5 minutes, or repetitive clinical or electrical seizures without return to baseline in between), <b>or</b></p>
<p style="text-indent:0em;text-align:left;">motor findings<sup>d</sup> (deep focal motor weakness such as hemiparesis or paraparesis), <b>or</b></p>
<p style="text-indent:0em;text-align:left;">raised intracranial pressure/cerebral edema<sup>d</sup>, with signs/symptoms including diffuse cerebral edema on neuroimaging, or decerebrate or decorticate posturing, or cranial nerve VI palsy, or papilledema, or Cushing triad</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue teclistamab.</p>
<p style="text-indent:0em;text-align:left;">Manage as per grade 2 ICANS. Alternatively, instead of dexamethasone, consider methylprednisolone 1,000 mg IV daily and continue methylprednisolone 1,000 mg IV daily for ≥2 days.</p>
<p style="text-indent:0em;text-align:left;">Provide supportive therapy as clinically appropriate (may include intensive care).</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Recommended Teclistamab Dosage Modifications for Other Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Actions</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until ANC is ≥500/mm<sup>3</sup>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Febrile neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until ANC is ≥1,000/mm<sup>3</sup> and fever resolves.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hemoglobin &lt;8 g/dL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until hemoglobin is ≥8 g/dL.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;25,000/mm<sup>3</sup>
<b>or</b> platelets 25,000 to 50,000/mm<sup>3</sup> with bleeding</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until platelets are ≥25,000/mm<sup>3</sup> and no evidence of bleeding.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypersensitivity reactions (systemic or local)</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">Withhold or consider permanently discontinuing teclistamab based on reaction severity.</p></td></tr>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;text-align:left;">Infections</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">Monitor immunoglobulin levels during treatment; manage according to guidelines, including infection precautions and antibiotic/antiviral prophylaxis.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab for active infection during the step-up dosing schedule.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold subsequent teclistamab treatment doses until infection improves to ≤ grade 1.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Consider permanent discontinuation of teclistamab. If not permanently discontinued, withhold subsequent treatment doses until infection improves to ≤ grade 1.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Other nonhematologic adverse reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold teclistamab until adverse reaction improves to ≤ grade 1.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Consider permanent discontinuation of teclistamab. If not permanently discontinued, withhold subsequent treatment doses until adverse reaction improves to ≤ grade 1.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F57460458"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F57438833"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (16%), edema (13%), hypertension (12%), hypotension (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (68%), decreased serum calcium (corrected: 31%), decreased serum phosphate (38%), decreased serum sodium (35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (18%), decreased appetite (11%), diarrhea (21%; grade 3: 2%), nausea (25%; grade 3: &lt;1%), vomiting (12%; grade 3: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (67%; grades 3/4: 33%), decreased neutrophils (84%; grades 3/4: 56%), decreased platelet count (71%; grades 3/4: 22%), decreased white blood cell count (86%; grades 3/4: 41%), hemorrhage (12%; grades 3/4: 2%), hypogammaglobulinemia (11%; grade 3: 1%), lymphocytopenia (92%; grades 3/4: 84%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (37%), increased serum alanine aminotransferase (28%), increased serum alkaline phosphatase (42%), increased serum aspartate aminotransferase (34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Cytokine release syndrome (72%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (30%, including opportunistic infection and serious infection; sepsis [6%]; viral infection [&lt;10%; including reactivation of HBV, cytomegalovirus, varicella zoster virus, and herpes simplex virus])</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (37%; including bruising at injection site, cellulitis at injection site, erythema at injection site, hematoma at injection site, induration at injection site, inflammation at injection site, injection-site pruritus, rash at injection site, swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (16%), encephalopathy (13%), fatigue (33%; including asthenia), headache (25%), motor dysfunction (16%; including abnormal gait, cogwheel rigidity, hypokinesia, muscle rigidity, muscle spasm, myasthenia, nerve palsy [sixth nerve palsy], psychomotor agitation, tremor, voice disorder), neurotoxicity (57%; including immune effector cell-associated neurotoxicity syndrome [6%]), pain (15%), peripheral sensory neuropathy (15%; including dysesthesia, hypoesthesia, neuralgia, oral hypoesthesia, oral paresthesia, paresthesia, sciatica)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (44%), ostealgia (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (11%), increased serum creatinine (30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (15%), hypoxia (18%), pneumonia (24%), upper respiratory tract infection (26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (76%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Guillain-Barre syndrome, seizure</p></div>
<div class="block coi drugH1Div" id="F57428732"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to teclistamab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F57460440"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cytokine release syndrome: Cytokine release syndrome (CRS), including fatal or life-threatening reactions, may occur; recurrent CRS has also been reported in approximately one-third of patients. Most patients experienced CRS following step-up dose 1, step-up dose 2, or the initial treatment dose. Only a small percentage of patients experienced first occurrence of CRS with subsequent teclistamab doses. The median time to onset of CRS was 2 days (range: 1 to 6 days) after the most recent dose and the median duration was 2 days (range: 1 to 9 days). Common manifestations of CRS included (but were not limited to) fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated liver enzymes. Patients should seek immediate medical attention if signs/symptoms of CRS occur at any time.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cytopenias: Teclistamab may cause neutropenia and febrile neutropenia. Neutropenia was reported in the majority of patients, with grade 3 or 4 neutropenia in over 50% of patients; febrile neutropenia occurred in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatotoxicity may occur with teclistamab, including fatalities. Elevated AST and ALT occurred in over one-third and one-quarter of patients, respectively, with a small percentage of grade 3 or 4 elevations; total bilirubin elevations (including grade 3 or 4 events) were also reported. Liver enzyme elevation may occur with or without concurrent CRS.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Teclistamab may cause both systemic and local injection site–related reactions. A small number of patients experienced systemic administration reactions, which consisted of grade 1 recurrent pyrexia and grade 1 swollen tongue. Over one-third of patients developed injection-site reactions; most reactions were grade 1, with some grade 2 events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Teclistamab may cause severe, life-threatening, or fatal infections. Serious infections (including opportunistic infections) occurred in almost one-third of patients, with a similar percentage of grade 3 or 4 infections; fatal infection was reported in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurologic toxicity: Teclistamab may cause serious or life-threatening neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS). In a clinical trial, over 50% of patients experienced neurologic toxicity, with grade 3 or 4 events occurring in some. Headache, motor dysfunction, sensory neuropathy, and encephalopathy were the most frequently reported neurologic toxicities. Grade 4 seizure and a case of fatal Guillain-Barre syndrome were reported with longer follow-up. ICANS was observed in some patients; most patients experienced ICANS following step-up dose 1, step-up dose 2, or the initial treatment dose. A small number of patients developed ICANS following subsequent doses. The median time to ICANS onset was 4 days (range: 2 to 8 days) with a median duration of 3 days (range: 1 to 20 days). Confusional state and dysgraphia were the most common ICANS clinical manifestations. The onset of ICANS may be concurrent with, following resolution of, or in the absence of CRS. Patients are at risk of depressed level of consciousness; advise patients to not drive or operate heavy or potentially dangerous machinery during and for 48 hours after completion of the step-up dosing schedule and with new onset of any neurologic toxicity symptoms until resolution.</p></div>
<div class="block foc drugH1Div" id="F57448401"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tecvayli: Teclistamab-cqyv 30 mg/3 mL (10 mg/mL) (3 mL); Teclistamab-cqyv 153 mg/1.7 mL (90 mg/mL) (1.7 mL) [contains edetate (edta) disodium]</p></div>
<div class="block geq drugH1Div" id="F57448399"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57509867"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tecvayli Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/3 mL (per mL): $708.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">153 mg/1.7 mL (per mL): $6,372.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58872671"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tecvayli: Teclistamab-cqyv 30 mg/3 mL (10 mg/mL) (3 mL); Teclistamab-cqyv 153 mg/1.7 mL (90 mg/mL) (1.7 mL) [contains edetate (edta) disodium]</p></div>
<div class="block accres drugH1Div" id="F57460434"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Tecvayli is available through specialty distributors. Information is available at https://janssenlabels.com/package-insert/product-patient-information/TECVAYLI-specialty-flashcard.pdf.</p></div>
<div class="block adm drugH1Div" id="F57460469"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Administer SUBQ into the abdomen (preferred injection site); may be administered at other sites (eg, thigh). Doses requiring &gt;2 mL total volume should be equally divided into multiple syringes. If multiple injection sites are required, they should be at least 2 cm apart. Do not inject into tattoos, scars, or areas where the skin is red, bruised, tender, hard, or not intact. For SUBQ administration only.</p>
<p style="text-indent:-2em;margin-left:4em;">Administer in a facility with adequate personnel and appropriate equipment to manage severe adverse reactions.</p></div>
<div class="block meg drugH1Div" id="F58698721"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Tecvayli: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761291s004lbl.pdf%23page%3D28&amp;token=tSxp77allQa08oZlNu8RNaTKrRLD%2ByoE4vyI%2FYpRuMZCc7sEw4pv4Q8fJYbYWwyhoCCiqSupbTsRRjr0F7QIpKKYOKWf52B%2BPQIk5E00mnuA8zThqsm7m7mSo9ANA2Hl&amp;TOPIC_ID=139997" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761291s004lbl.pdf#page=28</a></p></div>
<div class="block use drugH1Div" id="F57428731"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Multiple myeloma, relapsed or refractory:</b> Treatment of relapsed or refractory multiple myeloma in adults who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.</p></div>
<div class="block mst drugH1Div" id="F57460429"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Teclistamab may be confused with belantamab vedotin, tafasitamab, Tecentriq, tremelimumab.</p>
<p style="text-indent:-2em;margin-left:4em;">Tecvayli may be confused with Talvey.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57448490"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57448487"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Teclistamab may increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57460436"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 5 months after the last teclistamab dose.</p></div>
<div class="block pri drugH1Div" id="F57460437"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p>
<p style="text-indent:0em;margin-top:2em;">Teclistamab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action, in utero exposure to teclistamab may cause fetal harm. Due to risk of hypogammaglobulinemia, consider assessing immunoglobulin levels of newborns exposed to teclistamab in utero.</p></div>
<div class="block brc drugH1Div" id="F57460438"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if teclistamab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 5 months after the last dose of teclistamab.</p></div>
<div class="block mop drugH1Div" id="F57460471"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">Monitor blood counts, liver enzymes, and bilirubin at baseline and periodically during therapy. Monitor immunoglobulin levels during treatment. Consider laboratory testing to monitor for disseminated intravascular coagulation, as well as pulmonary, cardiac, and renal function. Verify pregnancy status prior to treatment initiation (in patients who could become pregnant).</p>
<p style="text-indent:0em;margin-top:2em;">Due to the risk for cytokine release syndrome (CRS) and neurologic toxicity, patients should be hospitalized for 48 hours after administration of teclistamab step-up doses including the first treatment dose. Monitor for CRS (signs/symptoms may include fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated liver enzymes) and signs/symptoms of neurologic toxicity. Monitor for signs/symptoms of infection (before and after treatment), monitor for signs of systemic or local hypersensitivity reactions.</p>
<p style="text-indent:0em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F57460444"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;">Teclistamab is a humanized immunoglobulin G4-proline, alanine, alanine (IgG4-PAA) antibody, and bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. Teclistamab binds to the CD3 receptor on the surface of T-cells, and BCMA expressed on the surface of multiple myeloma cells, which results in T-cell activation, the release of various proinflammatory cytokines, and the lysis of BCMA-expressing multiple myeloma cells (Moreau 2022).</p></div>
<div class="block phk drugH1Div" id="F57460445"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 5.63 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: 72%.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 139 hours (range: 19 to 168 hours) after the first treatment dose; 72 hours (range: 24 to 168 hours) after the 13th treatment dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: Decreases over time; mean clearance is 0.472 L/day at the 13th treatment dose.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847712"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Tecvayli</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048 doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24876563">
<a name="24876563"></a>Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood.</i> 2014;124(2):188-195. doi:10.1182/blood-2014-05-552729<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/24876563/pubmed" id="24876563" target="_blank">24876563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37269857">
<a name="37269857"></a>Ludwig H, Terpos E, van de Donk N, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. <i>Lancet Oncol</i>. 2023;24(6):e255-e269. doi:10.1016/S1470-2045(23)00159-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/37269857/pubmed" id="37269857" target="_blank">37269857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36991547">
<a name="36991547"></a>Martin TG, Mateos MV, Nooka A, et al. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. <i>Cancer</i>. 2023;129(13):2035-2046. doi:10.1002/cncr.34756<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/36991547/pubmed" id="36991547" target="_blank">36991547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24667956">
<a name="24667956"></a>Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. <i>Cancer J</i>. 2014;20(2):119-122. doi:10.1097/PPO.0000000000000035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/24667956/pubmed" id="24667956" target="_blank">24667956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35661166">
<a name="35661166"></a>Moreau P, Garfall AL, van de Donk NW, et al. Teclistamab in relapsed or refractory multiple myeloma. <i>N Engl J Med.</i> 2022;387(6):495-505. doi:10.1056/NEJMoa2203478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/35661166/pubmed" id="35661166" target="_blank">35661166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teclistamab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.1">
<a name="Janssen.1"></a>Tecvayli (teclistamab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2023.</div>
</li>
<li>
<div class="reference">
                  Tecvayli (teclistamab) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; July 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 139997 Version 44.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
